MOXYLON CV 625 is a broad-spectrum beta-lactamase resistant antibiotic combination tablet. The addition of Clavulanic Acid to Amoxycillin extends its spectrum of activity, making it effective against resistant organisms causing respiratory, urinary tract, skin and soft tissue infections.
Beta-lactamase inhibitor combination for extended spectrum
Effective against resistant bacterial strains
Film-coated tablets for ease of swallowing
Well-established safety and efficacy profile
Broad-spectrum antibacterial coverage
Treats respiratory tract infections including pneumonia and sinusitis
Effective for urinary tract infections
Management of skin and soft tissue infections
Covers gram-positive and gram-negative bacteria
Reduces treatment failure due to bacterial resistance
